T1	PROC 46 96	Estudio para evaluar la efectividad y la seguridad
T2	CHEM 100 111	efzofitimod
T3	LIVB 115 124	pacientes
#1	AnnotatorNotes T3	C0030705; Patients; Patient or Disabled Group
T4	DISO 129 149	sarcoidosis pulmonar
#2	AnnotatorNotes T4	C0036205; Sarcoidosis, Pulmonary; Disease or Syndrome
T5	PROC 172 244	Estudio de fase 3, aleatorizado, en doble ciego y controlado con placebo
T6	PROC 251 285	evaluar la eficacia y la seguridad
T7	CHEM 289 300	efzofitimod
T8	Route 301 312	intravenoso
T9	LIVB 316 325	pacientes
#3	AnnotatorNotes T9	C0030705; Patients; Patient or Disabled Group
T10	DISO 330 350	sarcoidosis pulmonar
#4	AnnotatorNotes T10	C0036205; Sarcoidosis, Pulmonary; Disease or Syndrome
T11	DISO 374 394	Sarcoidosis pulmonar
#5	AnnotatorNotes T11	C0036205; Sarcoidosis, Pulmonary; Disease or Syndrome
T12	PROC 423 434	Diagnóstico
#6	AnnotatorNotes T12	C0011900; Diagnosis; Diagnostic Procedure
T13	DISO 449 469	sarcoidosis pulmonar
#7	AnnotatorNotes T13	C0036205; Sarcoidosis, Pulmonary; Disease or Syndrome
T14	Duration 481 497	al menos 6 meses
T15	PROC 538 549	diagnóstico
#8	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 553 564	sarcoidosis
#9	AnnotatorNotes T16	C0036202; Sarcoidosis; Disease or Syndrome
T17	PROC 590 606	histológicamente
T18	PROC 611 628	biopsia de tejido
T19	DISO 655 689	afectación del parénquima pulmonar
T20	PROC 699 719	pruebas radiológicas
T21	DISO 742 774	sarcoidosis pulmonar sintomática
T22	LIVB 980 989	pacientes
#10	AnnotatorNotes T22	C0030705; Patients; Patient or Disabled Group
T23	Duration 1046 1056	>= 3 meses
T24	Dose 1061 1070	una dosis
T25	Dose 1085 1100	>=7,5 y <=25 mg
T26	Frequency 1100 1104	/día
T27	PROC 1108 1121	Peso corporal
T28	PROC 1168 1179	Tratamiento
#11	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	CHEM 1187 1201	inmunosupresor
#12	AnnotatorNotes T29	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T30	Route 1202 1206	oral
T31	PROC 1210 1221	Tratamiento
#13	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	CHEM 1226 1254	inmunomoduladores biológicos
#14	AnnotatorNotes T32	C1527392; Immunomodulators; Immunologic Factor · Pharmacologic Substance
T33	CHEM 1265 1312	inhibidores del factor de necrosis tumoral alfa
T34	CHEM 1314 1322	FNT-alfa
T35	CHEM 1326 1340	antifibróticos
T36	CHEM 1343 1373	inhibidores de la interleucina
T37	Spec_cue 1377 1392	Probabilidad de
T38	DISO 1393 1410	fibrosis pulmonar
#15	AnnotatorNotes T38	C0034069; Pulmonary Fibrosis; Disease or Syndrome
T39	Speculated 1393 1410	fibrosis pulmonar
T40	DISO 1483 1491	Fibrosis
#16	AnnotatorNotes T40	C0016059; Fibrosis; Pathologic Function
T41	PROC 1498 1520	TAC de alta resolución
T42	PROC 1544 1547	FVC
T43	DISO 1599 1620	Hipertensión pulmonar
#17	AnnotatorNotes T43	C0020542; Pulmonary Hypertension; Pathologic Function
T44	PROC 1661 1672	tratamiento
#18	AnnotatorNotes T44	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T45	CHEM 1677 1692	vasodilatadores
#19	AnnotatorNotes T45	C0042402; Vasodilator Agents; Pharmacologic Substance
T46	LIVB 1696 1705	Pacientes
#20	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	DISO 1710 1730	sarcoidosis cardíaca
T48	DISO 1732 1748	neurosarcoidosis
T49	DISO 1751 1768	sarcoidosis renal
T50	DISO 1772 1800	Sarcoidosis cutánea u ocular
T51	DISO 1848 1868	síntomas adisonianos
T52	Neg_cue 1873 1883	impidieron
T53	Negated 1911 1931	reducción progresiva
T54	CHEM 1939 1942	OCS
T55	DISO 1946 1953	Fumador
#21	AnnotatorNotes T55	C0337664; Smoker; Finding
T56	CHEM 2002 2008	tabaco
#22	AnnotatorNotes T56	C0040329; Tobacco; Hazardous or Poisonous Substance · Organic Chemical
T57	CHEM 2009 2017	nicotina
#23	AnnotatorNotes T57	C0028040; nicotine; Hazardous or Poisonous Substance · Organic Chemical
T58	DISO 2037 2059	síndrome antisintetasa
T59	CHEM 2076 2080	Jo-1
T60	PROC 829 895	escala de disnea modificada del Consejo de Investigaciones Médicas
T61	PROC 897 900	MRC
T62	PROC 959 967	KSQ-Lung
T63	PROC 1583 1591	KSQ-Lung
T64	PROC 1015 1026	tratamiento
T65	CHEM 1031 1034	OCS
T66	PROC 1911 1931	reducción progresiva
T67	CONC 829 856	escala de disnea modificada
T68	Result_or_Value 931 941	al menos 1
T69	CONC 962 963	-
T70	Result_or_Value 968 973	<=70.
T71	Result_or_Value 1122 1139	>=40 kg y <160 kg
T72	Quantifier_or_Qualifier 1184 1186	>1
T73	Quantifier_or_Qualifier 1244 1254	biológicos
T74	Quantifier_or_Qualifier 1411 1424	significativa
T75	Result_or_Value 1521 1526	>20 %
T76	Result_or_Value 1548 1565	<50 % del teórico
T77	CONC 1583 1591	KSQ-Lung
T78	Result_or_Value 1592 1596	<30.
T79	Quantifier_or_Qualifier 1621 1647	clínicamente significativa
T80	Quantifier_or_Qualifier 1801 1828	clínicamente significativas
T81	Quantifier_or_Qualifier 1954 1960	activo
T82	Result_or_Value 2062 2070	positivo
T83	CONC 2087 2100	momento basal
T84	Patient 115 124	pacientes
T85	Patient 316 325	pacientes
T86	History_of 699 719	pruebas radiológicas
T87	Patient 980 989	pacientes
T88	Patient 1696 1705	Pacientes
T89	History_of 1848 1868	síntomas adisonianos
T90	History_of 1911 1920	reducción
T91	History_of 2037 2059	síndrome antisintetasa
